1-4 of 4
Theresa M. LaVallee
Close
Sort by
Journal Articles

Inhibition of Multiple Myeloma Tumor Growth and FGFR3 by the Aurora-Angiogenesis Inhibitor ENMD-981693.

Todd A. Hembrough, Xiaoru Chen, Patricia A. Burke, Glenn M. Swartz, Kathleen Bengali, Richard Brokx, Theresa M. LaVallee, Mark R. Bray
Journal: Blood
Blood (2007) 110 (11): 1209.
https://doi.org/10.1182/blood.V110.11.1209.1209
Published: 2007
Journal Articles

ENMD-981693 Is an Orally-Active Kinase Inhibitor with Activity towards Human Hematologic Cancers In Vitro and In Vivo .

Mark R. Bray, PhD, Graham C. Fletcher, PhD, Trisha A. Denny, John Xu, PhD, Xiaoru Chen, Patricia A. Burke, PhD, Wanda Franklin, Theresa M. LaVallee, PhD, Mark D. Minden, MD, PhD, Carolyn F. Sidor, MD, MBA
Journal: Blood
Blood (2006) 108 (11): 1377.
https://doi.org/10.1182/blood.V108.11.1377.1377
Published: 2006
Journal Articles

2-Methoxyestradiol in Combination with Velcade® Results in an Augmentation of NFκB Inhibition, In Vitro Antiproliferative Activity and In Vivo Antitumor Efficacy in the RPMI-8226 Myeloma Model.

Patricia Burke, PhD, Glenn M. Swartz, B.S., Cassandra L. Waters, B.S., Xiaoru Chen, M.D., Theresa M. LaVallee, Ph.D., Anthony M. Treston, Ph.D., William E. Fogler, Ph.D., Carolyn F. Sidor, MD
Journal: Blood
Blood (2006) 108 (11): 3521.
https://doi.org/10.1182/blood.V108.11.3521.3521
Published: 2006
Journal Articles

MKC-1 Is a Novel Agent That Induces Cell Cycle Arrest and Disrupts Multiple Survival Pathways in Hematologic Cancers.

Trisha A. Denny, Xiaoru Chen, Cassandra L. Waters, Patricia A. Burke, PhD, Graham C. Fletcher, PhD, John Xu, PhD, Carolyn F. Sidor, MD, MBA, Mark D. Minden, MD, PhD, Theresa M. LaVallee, PhD, Mark R. Bray, PhD
Journal: Blood
Blood (2006) 108 (11): 4390.
https://doi.org/10.1182/blood.V108.11.4390.4390
Published: 2006